A
Angelo Viscido
Researcher at University of L'Aquila
Publications - 105
Citations - 3543
Angelo Viscido is an academic researcher from University of L'Aquila. The author has contributed to research in topics: Ulcerative colitis & Crohn's disease. The author has an hindex of 30, co-authored 93 publications receiving 3097 citations. Previous affiliations of Angelo Viscido include Policlinico Umberto I & Sapienza University of Rome.
Papers
More filters
Journal ArticleDOI
Evaluation of Crohn disease activity with magnetic resonance imaging
Francesca Maccioni,Angelo Viscido,Broglia L,M. Marrollo,R. Masciangelo,R. Caprilli,Plinio Rossi +6 more
TL;DR: An excellent statistical correlation was found between biologically “active” disease and the following MRI parameters: wall gadolinium enhancement, wall hyperintensity on T1-weighted fat-suppressed images, and hyperintensity of fibrofatty proliferation on T2-weighting fat-Suppressed images.
Journal ArticleDOI
MR Imaging in Patients with Crohn Disease: Value of T2- versus T1-weighted Gadolinium-enhanced MR Sequences with Use of an Oral Superparamagnetic Contrast Agent
Francesca Maccioni,Antonio Bruni,Angelo Viscido,Maria Chiara Colaiacomo,A. Cocco,Chiara Montesani,Renzo Caprilli,Mario Marini +7 more
TL;DR: T2-weighted MR can depict Crohn disease lesions and help assess mural and transmural inflammation with the same accuracy as gadolinium-enhanced T1- and T2- Weighted MR.
Journal ArticleDOI
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up
Anna Kohn,Marco Daperno,Alessandro Armuzzi,Maria Cappello,Livia Biancone,Ambrogio Orlando,Angelo Viscido,Vito Annese,Gabriele Riegler,Gianmichele Meucci,M. Marrollo,R. Sostegni,Antonio Gasbarrini,S. Peralta,Cosimo Prantera +14 more
TL;DR: Severe ulcerative colitis is a life‐threatening disorder, despite i.v. glucocorticoids treatment, and infliximab has been proposed as a safe rescue therapy.
Journal ArticleDOI
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Giovanni Latella,Maria Teresa Pimpo,Sandra Sottili,Maddalena Zippi,Angelo Viscido,Maria Chiaramonte,Giuseppe Frieri +6 more
TL;DR: After 12 months the group treated with glucomannan + rifaximin showed fewer symptoms and a lower global symptomatic score, and cyclic administration of rifaxIMin is effective in obtaining symptom relief in uncomplicated diverticular disease of the colon.
Journal ArticleDOI
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
Cosimo Prantera,Angelo Viscido,Livia Biancone,Antonio Francavilla,Lucio Giglio,Massimo Campieri +5 more
TL;DR: Preliminary studies suggest that similar rates for induction of remission can be expected from 5‐ASA enemas and MMx for patients with left‐sided ulcerative colitis.